NAPSR News: AstraZeneca Obtains Positive Results from Phase III Trials For The Treatment of Gout

AstraZeneca’s Phase III program of lesinurad in combination with xanthine oxidase inhibitors produced optimistic results for gout patients. If approved, this combination therapy will add a significant boost to the company’s product pipeline.



via Marketing - Latest News http://ift.tt/1oK3bVb